Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223280 | 0.85 | ADRB2 (0.53) | ADRB2ADRB1ADRB3CES2CES1 | |
| SCHEMBL775620 | 0.83 | CES2 (0.59) | CES2CES1CA1CA2NPC1 | |
| SCHEMBL20548928 | 0.80 | ALDH1A1 (0.49) | CES2CES1CA1CA2NPC1 | |
| SCHEMBL20548908 | 0.80 | LMNA (0.53) | ADRB2ADRB1ADRB3NPC1RAB9A | |
| SCHEMBL29673261 | 0.80 | TDP1 (0.55) | ADRB2ADRB1ADRB3CES2CES1 | |
| SCHEMBL424471 | 0.80 | TDP1 (0.55) | ADRB2ADRB1ADRB3CES2CES1 | |
| SCHEMBL697038 | 0.80 | TDP1 (0.55) | ADRB2ADRB1ADRB3CES2CES1 | |
| SCHEMBL20548926 | 0.80 | CES2 (0.46) | CES2CES1CA1CA2NPC1 | |
| SCHEMBL1489599 | 0.80 | TDP1 (0.55) | ADRB2ADRB1ADRB3CES2CES1 | |
| SCHEMBL582331 | 0.79 | ALDH1A1 (0.57) | ADRB2ADRB1ADRB3CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111763209-B | Synthesis process of luccotinib | 正大天晴药业集团股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-3398952-B1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-07-14 | — | — | EP | disclosed |
| CN-111763209-A | Synthesis process of luccotinib | 正大天晴药业集团股份有限公司 | 2020-10-13 | — | — | CN | disclosed |
| CN-108699063-B | Synthesis process of luccotinib | 正大天晴药业集团股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10562904-B2 | Synthesis process of ruxolitinib | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-01-24 | — | — | US | disclosed |
| EP-3398952-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562904-B2 | Synthesis process of ruxolitinib | JAK3, JAK1, JAK2 | ADRB2 2283/4885ADRB1 2292/4885ADRB3 1678/4885 |
| US-20190023712-A1 | SYNTHESIS PROCESS OF RUXOLITINIB | JAK3, JAK1, JAK2 | ADRB2 2283/4885ADRB1 2292/4885ADRB3 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.